Angelini Ventures Invests in Epicrispr Biotechnologies' $90M Series C to Advance First-in-Class Epigenetic Therapy for FSHD 8/10/2026 Category:
NUCLIDIUM Closes CHF 105M Series B — Advancing Copper-Based Radiotheranostics into Clinical Proof-of-Concept 5/27/2026 Category:
Angelini Ventures Invests in Hypervision Surgical's £17M Series A to Advance Hyperspectral Imaging in Surgery 4/29/2026 Category: INVESTMENTS
Angelini Ventures